Radiopharmaceutical Therapy 2023
DOI: 10.1007/978-3-031-39005-0_21
|View full text |Cite
|
Sign up to set email alerts
|

Pretargeted Radiopharmaceutical Therapy

Outi M. Keinänen,
Brian M. Zeglis
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 53 publications
0
2
0
Order By: Relevance
“…11 C and 18 amino acids, peptides, and small biomolecules, have gained much attention for PET imaging in various disease conditions. 8 Carbon-11 allows isotopic labeling, and its radiochemistry has been well studied in recent decades, but its short half-life (20.4 min) limits its use. In this context, fluorine-18 is more commonly used in radiolabeling due to its longer half-life (110 min), which provides advantages in radiosynthesis steps and for transporting it to other institutes.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…11 C and 18 amino acids, peptides, and small biomolecules, have gained much attention for PET imaging in various disease conditions. 8 Carbon-11 allows isotopic labeling, and its radiochemistry has been well studied in recent decades, but its short half-life (20.4 min) limits its use. In this context, fluorine-18 is more commonly used in radiolabeling due to its longer half-life (110 min), which provides advantages in radiosynthesis steps and for transporting it to other institutes.…”
mentioning
confidence: 99%
“…In this context, fluorine-18 is more commonly used in radiolabeling due to its longer half-life (110 min), which provides advantages in radiosynthesis steps and for transporting it to other institutes. 8 Numerous studies have demonstrated that malignant tumors can be detected with high sensitivity and specificity using PET imaging. F]fluciclovine PET have been shown to detect nodal and osseous disease at higher rates compared to FDG-PET but offer no additional benefit in detecting prostate disease, especially in primary staging.…”
mentioning
confidence: 99%